Phathom Pharmaceuticals, Inc.
General ticker "PHAT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $585.2M (TTM average)
Phathom Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 56.2%.
Estimated limits based on current volatility of 4.3%: low 14.10$, high 15.37$
Factors to consider:
- Total employees count: 427 as of 2024
- Top business risk factors: Limited operating history, Need for additional capital, Operational and conduct risks, Dependence on key products, Market competition
- Current price 25.3% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [5.02$, 13.20$]
- 2025-12-31 to 2026-12-31 estimated range: [4.14$, 11.22$]
Financial Metrics affecting the PHAT estimates:
- Negative: with PPE of -1.6 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -53.70 <= 0.04
- Positive: Investing cash flow per share per price, % of -0.03 > -0.62
- Negative: Shareholder equity ratio, % of -67.03 <= 19.35
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
Short-term PHAT quotes
Long-term PHAT plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.68MM | $55.25MM |
| Operating Expenses | $172.44MM | $167.99MM | $332.72MM |
| Operating Income | $-172.44MM | $-167.31MM | $-277.47MM |
| Non-Operating Income | $-25.28MM | $-34.28MM | $-56.86MM |
| Interest Expense | $27.30MM | $41.97MM | $72.01MM |
| R&D Expense | $71.44MM | $49.90MM | $34.08MM |
| Income(Loss) | $-197.72MM | $-201.59MM | $-334.33MM |
| Profit(Loss)* | $-197.72MM | $-201.59MM | $-334.33MM |
| Stockholders Equity | $-74.81MM | $-72.76MM | $-253.58MM |
| Inventory | $0.00MM | $1.21MM | $3.21MM |
| Assets | $164.81MM | $413.84MM | $378.32MM |
| Operating Cash Flow | $-146.53MM | $-137.58MM | $-266.77MM |
| Capital expenditure | $1.04MM | $1.63MM | $0.14MM |
| Investing Cash Flow | $-1.04MM | $-1.63MM | $-0.14MM |
| Financing Cash Flow | $120.04MM | $367.58MM | $182.77MM |
| Earnings Per Share** | $-5.05 | $-3.93 | $-5.29 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.